Valneva SE Stock
Price
Target price
€3.61
€3.61
-1.800%
-0.066
-1.800%
€7.00
19.04.24 / Tradegate
WKN: A0MVJZ / Name: Valneva / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Valneva SE Stock
We can see a decrease in the price for Valneva SE. Compared to yesterday it has lost -€0.066 (-1.800%).
With 0 Sell predictions and 2 Buy predictions the community sentiment towards the Valneva SE stock is not clear.
As a result the target price of 7 € shows a very positive potential of 94.12% compared to the current price of 3.61 € for Valneva SE.
For the coming years our community has positive and negative things to say abot the Valneva SE stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Balance Sheet Risk" there were negative voices in the community.
Pros and Cons of Valneva SE in the next few years
Pros
?
C******** o* t** e**********
?
B****
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Valneva SE vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Valneva SE | -1.800% | -10.343% | -4.477% | -25.833% | -24.387% | -72.640% | 3.029% |
| Nanobiotix | -2.320% | -4.721% | -9.263% | 47.085% | -21.417% | -63.229% | -56.621% |
| Transgene S.A. | 2.690% | 5.985% | 30.811% | -26.741% | 8.358% | -44.368% | -49.671% |
| Quantum Genomics S.A. | 0.400% | -2.524% | 7.036% | -16.333% | 14.091% | -97.694% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-06-11
Upon initial examination, the financial standing of Valneva, a company in the Biotechnology & Medical Research industry, is a mix of strengths and weaknesses. The company appears to be investing heavily in research and development, which is typical for firms in this sector. However, a thorough analysis of their financial statements reveals several key areas of concern, as well as areas of opportunity.
*Pros: *
Increased Revenue: Valneva's revenue has been steadily increasing - from 110,321,000 EUR in 2020 to 348,085,000 EUR in 2021 and 361,303,000 EUR in 2022. This positive trend indicates that the company is successfully growing its business and generating higher income.
